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Laura Nuñom,  Gema  Bonillam,  Ignacio  Grafian,  Sergio  Prieto-Gonzálezn, Javier  Narvaezo,
Ernesto  Trallero-Araguasp,  Albert  Selva-O’Callaghanp,  Oreste  Gualilloq, Javier  Martínd,
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Objective:  To  investigate  the  human  leukocyte  antigen  (HLA)  association  with  anti-synthetase  syndrome
(ASSD).
Methods:  We  conducted  the  largest  immunogenetic  HLA-DRB1  and HLA-B  study  to date  in  a  homogeneous
cohort  of  168  Caucasian  patients  with  ASSD  and  486  ethnically  matched  healthy  controls  by  sequencing-
based-typing.
Results:  A  statistically  significant  increase  of  HLA-DRB1*03:01  and  HLA-B*08:01  alleles  in  patients  with
ASSD  compared  to  healthy  controls  was  disclosed  (26.2%  versus  12.2%,  P  =  1.56E–09,  odds  ratio–OR
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[95%  confidence  interval–CI]  =  2.54 [1.84–3.50]  and  21.4%  versus  5.5%,  P =  18.95E–18,  OR  [95%  CI]  =  4.73
[3.18–7.05];  respectively).  Additionally,  HLA-DRB1*07:01  allele  was  significantly  decreased  in  patients
with ASSD  compared  to  controls  (9.2%  versus  17.5%,  P  = 0.0003,  OR [95%  CI]  = 0.48  [0.31–0.72]).  Moreover,
a statistically  significant  increase  of HLA-DRB1*03:01  allele  in  anti-Jo-1  positive  compared  to anti-Jo-1
negative patients  with  ASSD  was  observed  (31.8%  versus  15.5%,  P =  0.001,  OR [95%  CI] = 2.54  [1.39–4.81]).
Similar  findings  were  observed  when  HLA  carrier  frequencies  were  assessed.  The  HLA-DRB1*03:01  associ-
ation  with  anti-Jo-1  was  unrelated  to smoking  history.  No  HLA  differences  in patients  with  ASSD  stratified
according  to the  presence/absence  of the  most representative  non-anti-Jo-1  anti-synthetase  autoantibod-
ies  (anti-PL-12  and  anti-PL-7),  arthritis,  myositis  or  interstitial  lung  disease  were  observed.
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1. Introduction
Anti-synthetase syndrome (ASSD) is a connective tissue disease
included in the idiopathic inflammatory myopathies (IIM) group,
characterised essentially by the typical clinical triad of arthritis,
myositis, and interstitial lung disease (ILD) [1–5]. Antiaminoacyl
tRNA-synthetase antibodies (anti-ARS) are the main markers of
ASSD, with anti-Jo-1 as the most frequent autoantibody identi-
fied in this condition [1,2,6,7]. Other anti-ARS, mainly anti-PL-12
and anti-PL-7, are less commonly found in ASSD [1,2,6,7]. The
etiopathogenesis of ASSD remains unclear, although some pieces
of evidence support the hypothesis that both genetic and environ-
mental factors may  play a relevant role [8].
The human leukocyte antigen (HLA) region encompasses a
group of genes that encodes the most polymorphic human pro-
teins, the class I and class II antigen-presenting molecules [9]. This
region is crucial in controlling the immune response and is impli-
cated in the pathogenesis of numerous diseases, mainly in those
involving autoimmune phenomena [10,11]. Previous studies per-
formed in heterogeneous groups of patients with different types of
IIM or small series of patients with ASSD have described a potential
association of HLA alleles with the development of anti-synthetase
autoantibodies [12–19]. Amongst them, alleles of the Caucasian
8.1 ancestral haplotype (mainly HLA-DRB1*03:01 and HLA-B*08:01)
were suggested as the major HLA risk factors implicated in this
process [12–19].
Taking all these considerations into account, we  aimed to further
establish the potential HLA implication in the etiopathogenesis of
ASSD by conducting the largest immunogenetic study performed
so far of HLA-DRB1 and HLA-B associations in a homogeneous and
well-defined cohort of Caucasian patients with ASSD.
2. Methods
2.1. Study population
A total of 168 unrelated Spanish patients of European ancestry
diagnosed with ASSD were enrolled in this study. Centres involved
in the recruitment of these patients included: Hospital Univer-
sitario Marqués de Valdecilla (Santander); Hospital Universitario
Clínico San Cecilio (Granada); Hospital Clínico Universitario de San-
tiago (Santiago de Compostela); Complejo Asistencial Universitario
de León (León); Hospital Universitario Araba (Vitoria); Hospital
Clínico de Barcelona, Hospital Universitario de Bellvitge and Hospi-
tal Universitario Valle de Hebrón (Barcelona); and Hospital General
Universitario Gregorio Marañón, Hospital Universitario Fundación
Jiménez Díaz, Hospital Universitario La Paz and Hospital Universi-
tario de la Princesa (Madrid).
Patients with a positive anti-synthetase antibody test on at
least two occasions, along with one or more findings of the typ-
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nti-synthetase autoantibodies were detected by the commercially
vailable myositis immunoblot kit ‘Euroline Autoimmune Inflam-
atory Myopathies 16 Ag kit’ (Euroimmun, Luebeck, Germany)
ccording to the manufacturer’s instructions. This kit detects,
mongst others, antibodies against the following tRNAs: Jo-1
histidyl-tRNA synthetase), PL-12 (alanyl-tRNA synthetase), PL-7
threonyl-tRNA synthetase), EJ (glycyl-tRNA synthetase) and OJ
isoleucyl-tRNA synthetase). In some cases, anti-Jo-1 antibodies
ere also assessed with commercially available ENA (extractable
uclear antigen) screen tests. Arthritis occurrence and its presenta-
ion pattern were clinically assessed by the treating rheumatologist
referent physician); myositis was defined by muscle enzyme
levation (creatinine phosphokinase and/or aldolase) and the pres-
nce of typical electromyography alterations and/or compatible
uscle biopsy findings and/or compatible muscle magnetic res-
nance; ILD was  defined instrumentally by a restrictive pulmonary
unction test pattern [forced vital capacity (FVC) ≤ 80%, forced expi-
atory volume in one second (FEV1)/FVC ≥ 70%], and/or diffusing
apacity of the lung for carbon monoxide (DLCO) < 80% and inter-
titial changes on high-resolution computed tomography of the
ungs [1,4,7,20–22]. Information on smoking history was also col-
ected. With respect to this, 69.2% of our patients were female,
edian age at disease onset was 48.0 [38.0–60.0] years and 42.6%
ere ever-smokers. The specificities of the immunological tests
n our patients were anti-Jo-1 in 65.5% (n = 110), anti-PL-12 in
3.7% (n = 23), anti-PL-7 in 13.1% (n = 22), anti-EJ in 1.8% (n = 3) and
nti-OJ in 0.6% (n = 1). Amongst the other specificities disclosed in
he immunoblot, Ro-52 was the most common, found in 39.3% of
ur patients (n = 66). In addition, arthritis, myositis and ILD were
resent in 61.3%, 71.4% and 91.1% of our patients, respectively. The
ccurrence of accompanying features, including fever, Raynaud’s
henomenon and mechanic’s hands were also assessed. Fever was
efined as a body temperature ≥ 38 ◦C for more than 10 days with
o evidence of an alternative cause. Raynaud’s phenomenon was
etermined as the occurrence of transient finger ischemia after
old exposure. Mechanic’s hands were defined as the occurrence
f a thickened, hyperkeratotic, and fissured aspect of the radial
ides of the fingers of the hands, in the absence of other causes
4,22,23]. Patients with other types of IIM were excluded from
ur study. Complete information on demographic and clinical fea-
ures of the patients with ASSD enrolled in this study is displayed
n Table S1 [Appendix A; See the supplementary material associ-
ted with this article online].
The control population included 486 ethnically matched
naffected individuals with no history of autoimmune disease,
omprised by blood donors from Hospital Universitario Marqués
e Valdecilla (Santander) and National DNA Bank Repository (Sala-
anca).
All patients and healthy controls gave their informed consent
or inclusion before they participated in the study. The study was
onducted in accordance with the Declaration of Helsinki and all
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Table  1
HLA-DRB1 allele frequencies in patients with ASSD and healthy controls.
HLA-DRB1 Patients with ASSD
(2n  = 336)
Healthy controls (2n = 972) OR [95% CI]
DRB1*01 01:01 5.4 (18) 6.0 (58) 0.89 [0.49–1.56]
01:02 3.9 (13) 5.6 (54) 0.68 [0.34–1.29]
01:03 0.6 (2) 0.6 (6) 0.96 [0.09–5.42]
DRB1*03 03:01 26.2 (88)a 12.2 (119)a 2.54 [1.84–3.50]a
DRB1*04 04:01 1.5 (5) 2.7 (26) 0.55 [0.16–1.47]
04:02 2.1 (7) 2.0 (19) 1.07 [0.38–2.68]
04:03 1.5 (5) 0.5 (5) 2.92 [0.67–12.77]
04:04 2.7 (9) 3.5 (34) 0.76 [0.32–1.64]
04:05 4.8 (16) 2.4 (23) 2.06 [1.00–4.13]
04:07 0.6 (2) 0.6 (6) 0.96 [0.09–5.42]
04:08 0 0.2 (2) 0.00 [0.00–5.57]
DRB1*07 07:01 9.2 (31)a 17.5 (170)a 0.48 [0.31–0.72]a
DRB1*08 08:01 4.2 (14) 2.0 (19) 2.18 [1.00–4.64]
08:02 0 0.1 (1) –
08:03 1.2 (4) 0.4 (4) 2.92 [0.54–15.73]
DRB1*09 09:01 0 0.9 (9) 0.00 [0.00–1.23]
DRB1*10 10:01 0 2.3 (22) 0.00 [0.00–0.49]
DRB1*11 11:01 6.3 (21) 6.9 (67) 0.90 [0.52–1.52]
11:02 1.2 (4) 1.5 (15) 0.77 [0.18–2.43]
11:03 0 1.1 (11) 0.00 [0.00–1.00]
11:04 3.0 (10) 5.6 (54) 0.52 [0.23–1.05]
DRB1*12 12:01 0.3 (1) 0.7 (7) 0.41 [0.009–3.22]
DRB1*13 13:01 6.3 (21) 6.7 (65) 0.93 [0.53–1.57]
13:02 2.4 (8) 3.3 (32) 0.72 [0.28–1.61]
13:03 1.2 (4) 2.2 (21) 0.55 [0.14–1.63]
DRB1*14 14:01 1.5 (5) 1.9 (18) 0.80 [0.23–2.26]
14:04 0.9 (3) 0.9 (9) 0.96 [0.17–3.89]
DRB1*15 15:01 6.8 (23) 6.1 (59) 1.14 [0.66–1.91]
15:02 1.5 (5) 1.3 (13) 1.11 [0.31–3.37]
DRB1*16 16:01 3.3 (11) 2.1 (20) 1.61 [0.69–3.57]

























HLA: human leukocyte antigen; ASSD: anti-synthetase syndrome; OR: odds ratio; CI:
that  remained statistically significant after Bonferroni adjustment are highlighted i
a P < 0.001
experimental protocols were approved by the Ethics Committees
of clinical research of the corresponding centres (Hospital Uni-
versitario Marqués de Valdecilla, Hospital Universitario Clínico
San Cecilio, Hospital Clínico Universitario de Santiago, Complejo
Asistencial Universitario de León, Hospital Universitario Araba,
Hospital Clínico de Barcelona, Hospital Universitario de Bellvitge,
Hospital Universitario Valle de Hebrón, Hospital General Universi-
tario Gregorio Marañón, Hospital Universitario Fundación Jiménez
Díaz, Hospital Universitario La Paz and Hospital Universitario de la
Princesa).
2.2. HLA-DRB1 and HLA-B Typing
High-molecular-weight genomic DNA was extracted from
whole blood using the Maxwell 16 Blood DNA Purification Kit
(Promega Biotech Ibérica, S.L., Spain) according to the manufac-
turer’s instructions. All DNA samples were stored at −20 ◦C until
the HLA analysis.
DNA-based HLA-DRB1 and HLA-B typing were performed using
the high-resolution typing through a sequencing-based typing
(SBT) technique with the SBTexcellerator Kit and analysed with the
SBTengine-SBT HLA typing software (GenDx, Utrecht, The Nether-
lands).
2.3. Statistical Analysis
HLA-DRB1 and HLA-B allele and carrier frequencies were cal-
culated by direct counting. Comparisons between HLA-DRB1 and
HLA-B allele and carrier frequencies of patients with ASSD and
healthy controls as well as patients with ASSD stratified according
to antibody-specificity (presence/absence of anti-Jo-1, anti-PL-12






ence interval. Values are presented as percentages (number of individuals). Results
.
presence/absence of arthritis, myositis or ILD) were performed
sing the two-tailed chi-square test or the Fisher’s exact test when
ecessary (expected values < 5). The strength of association was
stimated using odds ratio (OR) and 95% confidence interval (CI).
esults were subjected to Bonferroni adjustment for multiple com-
arisons. After this adjustment, P-values < 0.05 were considered
tatistically significant.
Dependency of associations between HLA susceptibility signals
as  determined by a conditional logistic regression analysis in
hich the allelic dosage of the classic alleles associated with ASSD
n our analysis was added as a covariate.
Interaction of HLA and smoking for the development of anti-Jo-
 antibodies was  analysed by chi-square test and the strength of
ssociation was estimated using OR and 95% CI.
All analyses were performed using the software Plink (version
.07) [24]. Since Plink introduces a simple and efficient binary
ncoding for bi-allelic markers, HLA dataset was  converted into the
tandard Plink data input before the statistical analysis.
. Results
Firstly, HLA-DRB1 allele and carrier frequencies were compared
etween patients with ASSD and healthy controls. Table 1 shows
he HLA-DRB1 allele differences between these two groups. Of
ote, the frequency of HLA-DRB1*03:01 allele was significantly
ncreased in patients with ASSD when compared to healthy controls
26.2% versus 12.2%, P = 1.56E-09, OR [95% CI] = 2.54 [1.84–3.50])
Table 1). A statistically significant decrease of HLA-DRB1*07:01
llele in patients with ASSD compared to healthy controls was also
ound (9.2% versus 17.5%, P = 0.0003, OR [95% CI] = 0.48 [0.31–0.72])
Table 1). Similar results were disclosed when HLA-DRB1 car-
ier frequencies were compared between patients with ASSD and
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Table  2
HLA-B allele frequencies in patients with ASSD and healthy controls.
HLA-B Patients with ASSD
(2n  = 336)
Healthy controls (2n = 972) OR [95% CI]
HLA-B*07 07:02 4.2 (14) 7.0 (68) 0.58 [0.30–1.06]
07:05 0.9 (3) 1.1 (11) 0.79 [0.14–3.00]
HLA-B*08 08:01 21.4 (72)a 5.5 (53)a 4.73 [3.18–7.05]a
HLA-B*13 13:02 1.8 (6) 1.7 (17) 1.02 [0.33–2.74]
HLA-B*14 14:01 1.8 (6) 1.9 (18) 0.96 [0.31–2.56]
14:02 4.2 (14) 5.3 (52) 0.77 [0.39–1.43]
HLA-B*15 15:01 3.6 (12) 2.0 (19) 1.86 [0.81–4.08]
15:03  0.3 (1) 0.6 (6) 0.48 [0.01–4.00]
15:16 0 0.2 (2) 0.00 [0.00–5.57]
15:17 1.2 (4) 0.4 (4) 2.91 [0.54–15.73]
15:18  0.6 (2) 0.5 (5) 1.16 [0.11–7.11]
HLA-B*18 18:01 6.0 (20) 8.8 (86) 0.65 [0.37–1.09]
HLA-B*27 27:05 1.8 (6) 2.6 (25) 0.69 [0.23–1.74]
HLA-B*35 35:01 4.5 (15) 4.1 (40) 1.09 [0.55–2.05]
35:02 0.9 (3) 2.1 (20) 0.43 [0.08–1.46]
35:03 1.8 (6) 2.3 (22) 0.79 [0.26–2.02]
35:08 0.6 (2) 2.3 (22) 0.26 [0.03–1.06]
HLA-B*37 37:01 0.9 (3) 1.0 (10) 0.87 [0.15–3.39]
HLA-B*38 38:01 1.8 (6) 4.5 (44) 0.38 [0.13–0.91]
HLA-B*39 39:01 2.1 (7) 1.1 (11) 1.86 [0.61–5.30]
39:06  0.3 (1) 1.0 (10) 0.29 [0.007–2.03]
HLA-B*40 40:01 2.1 (7) 2.2 (21) 0.96 [0.34–2.38]
40:02 1.2 (4) 0.7 (7) 1.66 [0.35–6.58]
40:06 0 0.2 (2) 0.00 [0.00–5.57]
HLA-B*41 41:01 0.9 (3) 1.6 (16) 0.54 [0.10–1.90]
41:02 0 0.2 (2) 0.00 [0.00–5.57]
HLA-B*44 44:02 3.9 (13) 7.1 (69) 0.53 [0.26–0.98]
44:03 4.5 (15) 8.8 (86) 0.48 [0.25–0.85]
44:04 0.3 (1) 0.1 (1) 2.90 [0.04–227.74]
44:05 0 0.2 (2) 0.00 [0.00–5.57]
HLA-B*45 45:01 1.2 (4) 1.5 (15) 0.77 [0.18–2.43]
HLA-B*47 47:01 0.9 (3) 0.3 (3) 2.91 [0.39–21.81]
HLA-B*49 49:01 3.3 (11) 3.6 (35) 0.91 [0.41–1.85]
HLA-B*50 50:01 3.0 (10) 2.1 (20) 1.46 [0.60–3.31]
HLA-B*51 51:01 5.7 (19) 6.6 (64) 0.85 [0.47–1.46]
HLA-B*52 52:01 1.2 (4) 1.6 (16) 0.72 [0.17–2.25]
HLA-B*53 53:01 0.9 (3) 1.1 (11) 0.79 [0.14–3.00]
HLA-B*55 55:01 1.5 (5) 1.2 (12) 1.21 [0.33–3.72]
HLA-B*56 56:01 0.6 (2) 0.3 (3) 1.93 [0.16–16.95]
HLA-B*57 57:01 1.2 (4) 2.6 (25) 0.46 [0.11–1.34]
HLA-B*58 58:01 0.9 (3) 1.0 (10) 0.87 [0.15–3.39]
HLA-B*73 73:01 0.3 (1) 0.1 (1) 2.90 [0.04–227.74]


















that  remained statistically significant after Bonferroni adjustment are highlighted i
a P < 0.001
healthy controls. Accordingly, a statistically significant increase
of HLA-DRB1*03:01 and a statistically significant decrease of HLA-
DRB1*07:01 carriers were observed when patients with ASSD were
compared to healthy controls (50.6% versus 22.6%, P = 8.51E-12,
OR [95% CI] = 3.50 [2.38–5.15] and 17.9% versus 31.7%, P = 0.0006,
OR [95% CI] = 0.47 [0.29–0.74]; respectively) (Appendix A, Table
S2). These associations remained statistically significant after Bon-
ferroni correction. Regarding HLA-DRB1*03:01/HLA-DRB1*07:01
heterozygotes, no statistically significant differences were found
when patients with ASSD were compared to healthy controls (5.6%
versus 4.9%, respectively, P = 0.61, OR [95% CI] = 1.22 [0.51–2.71]).
Secondly, HLA-B allele and carrier frequencies were compared
between patients with ASSD and healthy controls (Table 2 and
Appendix A – Table S3). The strongest allele association was seen
for HLA-B*08:01, which was significantly increased in patients with
ASSD compared to healthy controls (21.4% versus 5.5%, P = 18.95E-
18, OR [95% CI] = 4.73 [3.18–7.05]) (Table 2). Also, a statistically
significant increase of HLA-B*08:01 carriers in patients with ASSD
compared to healthy controls was disclosed (42.3% versus 10.9%,
P = 3.96E-19, OR [95% CI] = 5.98 [3.85–9.29]) (Appendix A, Table








In a further step, we also assessed the potential dependency
etween the three HLA susceptibility signals mentioned above.
nterestingly, the association of HLA-DRB1*03:01 with ASSD sus-
eptibility remained statistically significant even after conditioning
y HLA-DRB1*07:01 and HLA-B*08:01, although a decrease on
he P-value was  observed when HLA-DRB1*03:01 association was
onditioned on HLA-B*08:01 (Table 3). This was  also the case
hen the association with HLA-DRB1*07:01, after conditioning
y HLA-DRB1*03:01 and HLA-B*08:01, and the association with
LA-B*08:01, after conditioning by HLA-DRB1*03:01 and HLA-
RB1*07:01, were assessed (Table 3).
Moreover, HLA-DRB1 and HLA-B allele and carrier frequencies
ere compared between patients with ASSD stratified according
o the presence/absence of anti-Jo-1, anti-PL-12 and anti-PL-7 anti-
odies and specific clinical features of the disease. In this regard, a
tatistically significant increase of HLA-DRB1*03:01 allele and carri-
rs in anti-Jo-1 positive patients with ASSD compared to anti-Jo-1
egative ones was detected (31.8% versus 15.5%, P = 0.001, OR [95%
I] = 2.54 [1.39–4.81] and 60.9% versus 31.0%, P = 0.0002, OR [95%
I] = 3.46 [1.68–7.24]) (Table 4 and Appendix A – Table S4). This
ssociation also remained statistically significant after Bonferroni
orrection. However, no statistically significant HLA-B allele and
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Table  3
Analysis for the dependency of the three HLA signals associated with the susceptibility to ASSD.
ASSD versus healthy controls







HLA-DRB1*03:01 2.48E-06 – 6.34E-05 0.026
HLA-DRB1*07:01 0.0003 0.009 – 0.004
HLA-B*08:01 1.40E-13 7.13E-07 1.33E-12 –
HLA: human leukocyte antigen; ASSD: anti-synthetase syndrome. P-values before and after conditioning calculated by logistic regression. Statistically significant results are
highlighted in bold.
Table 4
HLA-DRB1 allele frequencies in patients with ASSD stratified according to the presence/absence of anti-Jo1 antibodies.





DRB1*01 01:01 5.5 (12) 5.2 (6) 1.06 [0.36–3.53]
01:02 3.6 (8) 4.3 (5) 0.84 [0.24–3.34]
01:03 0.9 (2) 0 –
DRB1*03 03:01 31.8 (70)a 15.5 (18)a 2.54 [1.39–4.81]a
DRB1*04 04:01 1.4 (3) 1.7 (2) 0.79 [0.09–9.57]
04:02 1.4 (3) 3.4 (4) 0.39 [0.06–2.34]
04:03 1.4 (3) 1.7 (2) 0.79 [0.09–9.57]
04:04 1.4 (3) 5.2 (6) 0.25 [0.04–1.22]
04:05 4.5 (10) 5.2 (6) 0.87 [0.28–3.00]
04:07 0.9 (2) 0 –
04:08 0 0 –
DRB1*07 07:01 6.8 (15) 13.8 (16) 0.46 [0.20–1.03]
DRB1*08 08:01 5.0 (11) 2.6 (3) 1.98 [0.51–11.27]
08:02 0 0 –
08:03 0.9 (2) 1.7 (2) 0.52 [0.04–7.32]
DRB1*09 09:01 0 0 –
DRB1*10 10:01 0 0 –
DRB1*11 11:01 4.5 (10) 9.5 (11) 0.45 [0.17–1.22]
11:02 0.5 (1) 2.6 (3) 0.17 [0.003–2.18]
11:03 0 0 –
11:04 2.3 (5) 4.3 (5) 0.52 [0.12–2.30]
DRB1*12 12:01 0.5 (1) 0 –
DRB1*13 13:01 8.2 (18) 2.6 (3) 3.35 [0.95–18.12]
13:02 2.3 (5) 2.6 (3) 0.88 [0.17–5.74]
13:03 0.9 (2) 1.7 (2) 0.52 [0.04–7.32]
DRB1*14 14:01 1.4 (3) 1.7 (2) 0.79 [0.09–9.57]
14:04 1.4 (3) 0 –
DRB1*15 15:01 6.4 (14) 7.8 (9) 0.81 [0.31–2.19]
15:02 0.9 (2) 2.6 (3) 0.35 [0.03–3.07]
DRB1*16 16:01 3.2 (7) 3.4 (4) 0.92 [0.23–4.38]
16:02 0.5 (1) 0 –














adjustment are highlighted in bold. Values are presented as percentages (number o
a P < 0.01
carrier differences in patients with ASSD stratified according to
the presence/absence of anti-Jo-1 antibodies were found after the
adjustment by Bonferroni (Appendix A, Tables S5 and S6). This was
also the case when HLA-DRB1 and HLA-B allele and carrier frequen-
cies were compared in patients with ASSD stratified according to
the presence/absence of anti-PL-12 and anti-PL-7 antibodies (data
not shown).
Since an interrelationship between HLA-DRB1*03 and smoking
was postulated to promote anti-Jo-1 production in IIM [25], we
analysed the potential interaction of HLA-DRB1*03:01 and smoking
for the development of anti-Jo-1 antibodies in our patients with
ASSD. However, the frequency of anti-Jo-1 antibodies was simi-
lar in HLA-DRB1*03:01-positive non-smokers versus ever-smokers
(83.3% versus 80.0%, P = 0.72, OR [95% CI] = 1.25 [0.30–4.95])
(Appendix A, Table S7).No HLA-DRB1 or HLA-B differences in patients with ASSD strati-
fied according to the presence/absence of arthritis, myositis or ILD






Autoimmune inflammatory diseases are conditions charac-
erised by common pathogenic traits and overlap in genetic risk
26–28]. In this regard, the HLA region has been identified as the
ain genetic factor underlying immune-mediated diseases [29,30].
To the best of our knowledge, we report the largest immuno-
enetic study of HLA-DRB1 and HLA-B associations performed in a
omogeneous and well-defined cohort of Caucasian patients with
SSD. Our results revealed three HLA signals implicated in the
usceptibility to ASSD. In particular, the HLA-DRB1*03:01 and HLA-
1*08:01 alleles were identified as predisposition markers of ASSD
hereas HLA-DRB1*07:01 had a protective effect against this con-
ition. We  also disclosed an effect of the HLA on anti-Jo-1-positive
pecificity, pointing to HLA-DRB1*03:01 as a risk allele for the devel-
pment of these autoantibodies, irrespective of smoking status.
Alleles comprising the Caucasian 8.1 ancestral haplotype
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suggested as the major HLA risk factor related to ASSD in hetero-
geneous cohorts of patients with IIM or small series of patients
with ASSD [12–19]. The results derived from our large, homoge-
neous, and well-defined cohort of ASSD patients are in keeping
with those described in previous reports, supporting the role of
these alleles in the etiopathogenesis of ASSD. In this regard, the
8.1 ancestral haplotype is a common tightly conserved multigene
haplotype in Caucasians [31] that influences several aspects of the
immune response [32]. The constituent alleles of this haplotype are
implicated in the development of several highly prevalent autoim-
mune diseases, such as systemic lupus erythematosus [33,34],
systemic sclerosis [35], Sjögren syndrome [32] and myasthemia
gravis [36,37]. Accordingly, our findings provide evidence for a
shared genetic background in ASSD and other immunomediated
diseases, primarily those related to autoantibody production.
An influence of HLA-DRB1*07:01, as a protective factor against
the susceptibility to ASSD, was disclosed in our study. This is in
agreement with a previous report suggesting a potential asso-
ciation of HLA alleles unrelated to the Caucasian 8.1 ancestral
haplotype with ASSD [12].
Smoking has been linked to disease susceptibility and severity,
including the development of ILD, in some autoimmune diseases,
such as rheumatoid arthritis (RA) [38]. However, we  did not observe
the previously suggested interaction between smoking and HLA-
DRB1*03 for anti-Jo-1 development [25]. ILD in the context of RA has
been associated with the MUC5B rs35705950 genetic variant [39].
In contrast, a previous study of our group did not show association
of MUC5B rs35705950 with ILD in patients with ASSD [40]. These
results along with data showing a different HLA-DRB1 association
in RA-ILD (mostly linked to HLA-DRB1*04)  and ASSD suggest that
the mechanisms leading to ILD in RA and ASSD may  be different.
The differential diagnosis of ASSD is frequently challenging
since the clinical presentation of the disease is diverse and often
non-specific [2]. Consequently, patients with ASSD are frequently
under-diagnosed. Our results are of potential clinical relevance
since the characterisation of HLA together with the presence of spe-
cific clinical characteristics can help the clinician raise a flag for the
suspicion of ASSD.
In conclusion, our results support the association of the HLA
with the susceptibility to ASSD.
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